These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 8969681)

  • 1. Pharmaceuticals in the era of cost-containment.
    Bischof RO
    Hosp Pract (1995); 1996 Dec; 31(12):77-9, 83-4. PubMed ID: 8969681
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmaceutical cost containment and innovation in the United States.
    Kane NM
    Health Policy; 1997 Sep; 41 Suppl():S71-89. PubMed ID: 10174475
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacoeconomics and managed care: methodologic and policy issues.
    Luce BR
    Med Decis Making; 1998; 18(2 Suppl):S4-11. PubMed ID: 9566461
    [No Abstract]   [Full Text] [Related]  

  • 4. Forecasting the issues for managed care pharmacy.
    Navarro RP
    Am J Health Syst Pharm; 1998 Jan; 55(1):27-9. PubMed ID: 9437471
    [No Abstract]   [Full Text] [Related]  

  • 5. Drug Policy in Hungary.
    Inotai A; Csanádi M; Harsányi A; Németh B
    Value Health Reg Issues; 2017 Sep; 13():16-22. PubMed ID: 29073982
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug therapy: the impact of managed care.
    Hopkins J; Siu S; Cawley M; Rudd P
    Adv Pharmacol; 1998; 44():1-32. PubMed ID: 9547883
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparative experience in home care and pharmaceutical policy.
    Kane NM; Saltman RB
    Health Policy; 1997 Sep; 41 Suppl():S1-7. PubMed ID: 10174467
    [No Abstract]   [Full Text] [Related]  

  • 8. Legal challenges to managed care cost containment programs: an initial assessment.
    Jacobson PD
    Health Aff (Millwood); 1999; 18(4):69-85. PubMed ID: 10425844
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiology and cost control: the ethical challenge for the new millennium.
    Mattke S
    Z Kardiol; 2000 Aug; 89(8):649-57. PubMed ID: 11013969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Managed care pharmacy, socioeconomic assessments and drug adoption decisions.
    Lyles A; Luce BR; Rentz AM
    Soc Sci Med; 1997 Aug; 45(4):511-21. PubMed ID: 9226777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Health economics in primary care in the UK: containment of drug costs.
    Walley T; Edwards RT
    Pharmacoeconomics; 1993 Feb; 3(2):100-6. PubMed ID: 10146959
    [No Abstract]   [Full Text] [Related]  

  • 12. Pricing and reimbursement of pharmaceuticals: an evaluation of cost-containment strategies. Proceedings of a symposium. Talloires, France, July 21-22, 1993.
    Pharmacoeconomics; 1994; 6 Suppl 1():1-87. PubMed ID: 10184441
    [No Abstract]   [Full Text] [Related]  

  • 13. The emerging government requirement for economic evaluation of pharmaceuticals.
    Drummond M
    Pharmacoeconomics; 1994; 6 Suppl 1():42-50. PubMed ID: 10155586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The era of managed care: the struggle of cost containment and compassionate, effective care of persons with HIV/AIDS.
    Gallagher DM
    Nurs Clin North Am; 1999 Mar; 34(1):227-35. PubMed ID: 9922289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceuticals and medicare managed care: pharmacoeconomic considerations.
    Cox ER; Coons SJ
    Clin Ther; 1998; 20(6):1238-40. PubMed ID: 9916615
    [No Abstract]   [Full Text] [Related]  

  • 16. Medicaid preferred drug lists: cost containment and side effects.
    Headen AE
    Pharmacoeconomics; 2006; 24 Suppl 3():1-3. PubMed ID: 17266384
    [No Abstract]   [Full Text] [Related]  

  • 17. Who lost cost containment? A roster for recrimination.
    Hurley R; Rawlings RB
    Manag Care Q; 2001; 9(4):23-32. PubMed ID: 11813454
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reconceptualizing informed consent in an era of health care cost containment.
    Krause JH
    Iowa Law Rev; 1999 Oct; 85(1):261-386. PubMed ID: 12769114
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmaceutical expenditure in Sweden.
    Henriksson F; Hjortsberg C; Rehnberg C
    Health Policy; 1999 May; 47(2):125-44. PubMed ID: 10538288
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health policy versus industrial policy in the pharmaceutical sector: the case of Canada.
    Vandergrift M; Kanavos P
    Health Policy; 1997 Sep; 41(3):241-60. PubMed ID: 10170092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.